AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more
AC Immune Ltd (ACIU) - Total Assets
Latest total assets as of September 2025: $171.61 Million USD
Based on the latest financial reports, AC Immune Ltd (ACIU) holds total assets worth $171.61 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AC Immune Ltd - Total Assets Trend (2013–2024)
This chart illustrates how AC Immune Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AC Immune Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
AC Immune Ltd's total assets of $171.61 Million consist of 74.5% current assets and 25.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.7% |
| Accounts Receivable | $1.10 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $50.42 Million | 21.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how AC Immune Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AC Immune Ltd's current assets represent 74.5% of total assets in 2024, a decrease from 93.8% in 2013.
- Cash Position: Cash and equivalents constituted 15.7% of total assets in 2024, down from 88.2% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 21.8% of total assets.
AC Immune Ltd Competitors by Total Assets
Key competitors of AC Immune Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
AC Immune Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - AC Immune Ltd generates 0.12x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - AC Immune Ltd is currently not profitable relative to its asset base.
AC Immune Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 1.86 | 16.53 |
| Quick Ratio | 1.16 | 1.86 | 16.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.46 Million | $ 86.60 Million | $ 217.75 Million |
AC Immune Ltd - Advanced Valuation Insights
This section examines the relationship between AC Immune Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.82 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | 26.3% |
| Total Assets | $230.91 Million |
| Market Capitalization | $133.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values AC Immune Ltd's assets below their book value (0.58 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: AC Immune Ltd's assets grew by 26.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for AC Immune Ltd (2013–2024)
The table below shows the annual total assets of AC Immune Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $230.91 Million | +26.31% |
| 2023-12-31 | $182.81 Million | -1.68% |
| 2022-12-31 | $185.94 Million | -28.88% |
| 2021-12-31 | $261.44 Million | +9.51% |
| 2020-12-31 | $238.74 Million | -20.22% |
| 2019-12-31 | $299.25 Million | +52.25% |
| 2018-12-31 | $196.56 Million | +48.89% |
| 2017-12-31 | $132.01 Million | -15.43% |
| 2016-12-31 | $156.10 Million | +95.29% |
| 2015-12-31 | $79.93 Million | +163.83% |
| 2014-12-31 | $30.30 Million | +137.60% |
| 2013-12-31 | $12.75 Million | -- |